Melissa Maguire

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 7

Top Topics

Combination Therapy

Top Venues

Practical neurology

Health technology assessment (Winchester, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Sam Fairclough, Paul Chumas, John Robert Goodden, Melissa Maguire, Ryan Koshy Mathew
Motor seizures confer overall survival benefit in who grade 2 glioma. Epilepsia 65 (6) (2024)
Sam Fairclough, Paul Chumas, John Robert Goodden, Melissa Maguire, Ryan Koshy Mathew
Motor seizures confer overall survival benefit in who grade 2 glioma. Epilepsia 65 (6) (2024)
Sam Fairclough, Paul Chumas, John Robert Goodden, Melissa Maguire, Ryan Koshy Mathew
Motor seizures confer overall survival benefit in who grade 2 glioma. Epilepsia (2024)
Sam Fairclough, John Goodden, Paul Chumas, Ryan Mathew, Melissa Maguire
Levetiracetam as a first line antiseizure medication in WHO grade 2 glioma: time to seizure freedom and rates of treatment failure. Epilepsia (2023)
Linford Fernandes, Melissa Maguire, Mark S Igra, Ioannis A Mavroudis, Jeremy Cosgrove
Adult-onset leukoencephalopathy with calcifications and cysts. Practical neurology (2023)
Sam Fairclough, John Robert Goodden, Paul Chumas, Ryan Koshy Mathew, Melissa Maguire
Levetiracetam as a first-line antiseizure medication in WHO grade 2 glioma: Time to seizure freedom and rates of treatment failure. Epilepsia (2023)
Anthony G Marson, Girvan Burnside, Richard E Appleton, Dave Smith, John-Paul Leach, Graeme J Sills, Catrin Tudur-Smith, Catrin O Plumpton, Dyfrig A Hughes, Paula R Williamson, Gus Baker, Silviya Balabanova, Claire Taylor, Richard Brown, Dan Hindley, Stephen Howell, Melissa Maguire, Rajiv Mohanraj, Philip Em Smith
Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs. Health technology assessment (Winchester, England) 25 (75) (2022)